Several investigations showed that a novel anti-inflammation medicine, COX-2 inhibitor, disclosed potent anti-tumor activity in certain murine tumor models by extending the effectiveness of VEGFR inhibition in human renal cell carcinoma xenografts [1]. This evidence concerns the gene PTGS2 and hereditary clear cell renal cell carcinoma.